|drug3957||newborns from covid 19 positive mothers Wiki||1.00|
There is one clinical trial.
This is a retrospective analytical study conducted at Vascular and Endovascular surgery Department, Mansoura University Hospital, including all patients admitted at the two periods first six months of 2019 and 2020.To demonstrate the effect of COVID-19 pandemic on the practice of emergency vascular surgery and critical limb threatening ischemia interventions by comparison two periods first six months of 2019 and 2020.
Description: The ICU admission caused by Pneumonia proved radio-logically at both periodsMeasure: The ICU admission with associated Pneumonia Time: 6 months
Description: percentage of different diagnoses at both periodsMeasure: Impact of COVID-19 on the different presentation of vascular surgery at the emergency Time: 6 months
Description: Mortality percentages at both periodsMeasure: Mortality rates Time: 6 months
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports